Publications by authors named "Shenqi Lu"
Article Synopsis
- - Tyrosine kinase inhibitors (TKIs) have significantly improved treatment for Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), especially when paired with blinatumomab.
- - A study involving 19 Ph+ ALL patients showed remarkable outcomes: 100% overall response and 90% complete remission in newly diagnosed patients after one cycle of blinatumomab.
- - The combination treatment of blinatumomab and TKIs is both effective and safe, suggesting it could be a strong first-line therapy for Ph+ ALL patients.
Article Synopsis
- Blinatumomab shows effectiveness in treating B-cell acute lymphoblastic leukemia (B-ALL) but has limited real-world data, which this study aimed to address by analyzing its impact on Chinese patients with newly diagnosed (ND) and relapsed/refractory (R/R) B-ALL.
- The study included 96 B-ALL patients treated with at least one dose of blinatumomab, reporting significant outcomes such as a 100% complete remission (CR) rate for ND patients and a 50% CR rate for R/R patients, along with high rates of minimal residual disease (MRD) negativity.
- Overall, blinatumomab demonstrated a favorable safety profile, with only 12
Acute leukemia during pregnancy (P-AL) is a rare disease with limited data regarding the management and outcomes of mothers and fetuses. We retrospectively analyzed the characteristics, pregnancy outcomes and maternal and neonatal prognoses of 52 patients with P-AL collected from January 2013 to December 2020 in our center. Seventeen (32.
View Article and Find Full Text PDFClinical outcomes of hematopoietic stem cell transplantation (HSCT) using a haploidentical stem cell graft and an unrelated umbilical cord blood unit (haplo-cord HSCT) for the treatment of B cell acute lymphoblastic leukemia (B-ALL) remain unclear. This study was conducted to explore the clinical outcomes of haplo-cord HSCT in patients with B-ALL. A total of 112 B-ALL patients who underwent haplo-cord HSCT and 64 B-ALL patients who underwent haploidentical HSCT (haplo-HSCT) at our center between 2010 and 2020 were retrospectively included in this study, and clinical outcomes and prognostic factors were further analyzed.
View Article and Find Full Text PDFWe performed a retrospective study describing the characteristics of myeloid sarcoma (MS) and evaluated the outcome of hematopoietic stem cell transplantation (HSCT) in patients with MS. There were 27 patients with de novo isolated MS, 34 with de novo leukemic MS and 13 with secondary leukemic MS in our study. Sixty-three patients received induction chemotherapy.
View Article and Find Full Text PDF